ARRIS - Another partner Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (310)	12/9/1997 9:51:00 PM
From: Miljenko Zuanic	Read Replies (1) of 353

Thanks Peter. Agree that ARRS was/is cheap at current level with or without SQNA. But I can agree with TBF and others who thing that SQNA merge (with 10-15 % premium) are reasons for ARRS price decline (from 13.5 to 9.5 or ~40% decline). How should SQNA SH felt about this opposition to merge news? ARRS needs more SQNA than opposite and small premium (not 35%) is normal in this situation. What is the % of SQNA price devaluation in current ARRS price? I can't hide that I do like Delta technology (in theory), but how about real world, in vivo? Recent BMY deal is confirmation of the approach, but as James stated, how strong confirmation ??? Anyway, If I will have to decide between SQNA and ARRS (own both) I will chose SQNA. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next